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T
he utility of intravascular ultrasound (IVUS) guidance to improve the results of percutaneous coronary intervention (PCI) with drug-eluting stents (DES) remains controversial. In the large-scale, prospective, multicenter ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents), IVUS guidance of DES implantation was associated with reduced 1-year rates of stent thrombosis, myocardial infarction (MI), and composite major adverse cardiac events (MACE) compared with angiography guidance alone. 1 Based on IVUS evaluation, the operator changed interventional strategy and optimized the DES implantation procedure in 74% of cases. The IVUS-XPL randomized trial (Impact of Intravascular Ultrasound Guidance on Outcomes of Xience Prime Stents in Long Lesions) reported similar findings-IVUS guidance was associated with more postdilatation, use of larger balloon diameters, and improved 1-year outcomes. 2 However, few studies have examined whether the benefit of IVUS guidance is maintained, increases, or is lost beyond the 1-year follow-up period. We, therefore, assessed the impact of IVUS guidance on the long-term outcomes of PCI with DES from the ADAPT-DES study.
METHODS

Study Design and Protocol
The design, major inclusion and exclusion criteria, end points, and definitions from the ADAPT-DES study have been described in detail. 1, 3 Briefly, ADAPT-DES was a prospective, multicenter registry designed to determine the relation between platelet reactivity during dual therapy with aspirin and ADP receptor inhibitors and subsequent clinical outcomes after successful coronary DES implantation. All patients undergoing PCI with DES at participating centers were eligible for enrollment, regardless of comorbidities or lesion complexity. The only major exclusion criteria were the occurrence of a major periprocedural complication or planned bypass surgery after the PCI. Platelet reactivity was assessed after loading with aspirin and clopidogrel using the VerifyNow Aspirin, P2Y12, and IIb/ IIIa assays (Accumetrics, San Diego, CA).
ADAPT-DES included a prespecified substudy to determine the association between IVUS guidance of the DES implantation procedure and subsequent adverse events. Procedural IVUS use was per operator discretion. When IVUS was used, the operator was required to report how the IVUS information influenced the procedure. Clinical follow-up was scheduled at 30 days, 1 year, and 2 years. The study was approved by the institutional review board at each participating center; and all eligible patients signed informed, written consent. The data, analytic methods, and study materials are proprietary to the sponsor and will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
End Points and Definitions
The primary end point was definite or probable stent thrombosis according to the Academic Research Consortium criteria. 4 Additional end points included all-cause mortality, MI, repeat revascularization, stroke, and major bleeding. Death (all cause, cardiac, and noncardiac), MI (all, periprocedural, and spontaneous), and stent thrombosis (all and definite versus probable) were adjudicated by an independent clinical events committee, whereas the other events were site reported. 5, 6 MACE was defined as cardiac death, definite/ probable stent thrombosis, or MI.
Statistics
Categorical variables were compared between groups by χ 2 or Fisher exact test. Continuous variables were presented as mean±SD and were compared by Student t test. Time-toevent data were summarized as Kaplan-Meier estimates and were compared with the log-rank test. Landmark analysis was used to determine time-to-event rates between 1 and 2 years. A propensity score was constructed by modeling IVUS guidance in a logistic regression model with 73 clinical, procedural, and angiographic variables. Then, to determine the predictors of outcomes, variables historically considered clinically relevant were entered into multivariable Cox proportional hazards regression models stratified by the quintiles of the propensity score. Interaction testing by log-rank test was examined in clinically relevant subgroups. A P<0.05 was considered significant for all analyses. Statistical analyses were performed using SAS, version 9.1.3 (SAS Institute, Cary, NC).
RESULTS
Final Study Population and Follow-Up
From July 2008 to September 2010, 8663 patients were enrolled in ADAPT-DES at 11 sites in the United States and Germany. Eighty-one patients (0.9%) were excluded because of deviations in platelet function testing as reported previously. 3 Thus, the final study population consisted of 8582 patients. IVUS-guided stenting was performed in 3361 patients (39%), and angiography-guided stenting was performed in 5221 patients (61%). Follow-up at 2 years was complete in 7649
WHAT IS KNOWN
• Intravascular ultrasound-guided percutaneous coronary intervention improves long-term clinical outcome compared with angiography-guided percutaneous coronary intervention within 1 year.
• The benefit of intravascular ultrasound guidance is more pronounced in complex lesion subsets (chronic total occlusion, unprotected left main percutaneous coronary intervention, long lesions, etc).
WHAT THE STUDY ADDS
• In the contemporary drug-eluting stent era, the benefits of intravascular ultrasound guidance not only continue but increase from 1 to 2 years, especially in reducing target vessel-related spontaneous myocardial infarction and late revascularization.
patients (89.1%), including 3059 of 3361 (91.0%) in the IVUS-guided group and 4590 of 5221 (87.9%) in the angiography-guided group.
Baseline Characteristics and Procedural Data
As shown in Table 1 , several coronary risk factors were more prevalent in the angiography-guided group, whereas presentation with ST-segment-elevation MI and P2Y12 hyporesponsiveness to clopidogrel were more prevalent in the IVUS-guided group. 
Outcomes
Clinical outcomes at 2 years are shown in Table 3 and Figure 1 . The absolute difference in MACE that was present at 1 year between the 2 groups further increased with extended follow-up ( Figure 2 ). Comparing IVUS guidance to angiography guidance, the 1-year rates of MACE were 3.2% versus 4.8%, respectively (number needed to treat, 64; 95% CI, 42-137; hazard ratio, 0.67; 95% CI, 0.53-0.84). Between 1 and 2 years, MACE occurred in 1.9% of patients treated with IVUS guidance and 3.0% treated with angiography guidance (hazard ratio, 0.64; 95% CI, 0.47-0.86). Thus, the 2-year rates of MACE were 4.9% with IVUS guidance versus 7.5% with angiography guidance (number needed to treat, 41; 95% CI, 29-69; hazard ratio, 0.65; 95% CI, 0.54-0.78). Comparing IVUS guidance to angiography guidance, the 2-year rates of cardiac death were 1.7% versus 2.4%, P=0.03, and the trend was consistent within 1 year (0.9% versus 1.2%; P=0.11) and between years 1 and 2 (0.9% versus 1.2%; P=0.13). The stent thrombosis rate at 2 years was significantly lower with IVUS guidance than angiography guidance (0.55% versus 1.16%; P=0.004). Although the greatest difference occurred early after DES implantation, stent thrombosis between 1 and 2 years also trended toward lower in the IVUS guidance group compared with the angiography guidance group (0.06% versus 0.21%; P=0.11) as shown in the landmark analysis ( Figure 2 ).
The MI rate at 2 years was significantly lower with IVUS guidance compared with angiography guidance (3.5% versus 5.6%; P<0.0001), as well as between 1 and 2 years (1.1% versus 2.1%; P=0.002; Figure 2 ). The reduction of MI in the IVUS guidance group was primarily because of a reduction in both stent thrombosis-related MI and non-stent thrombosisrelated spontaneous MI. In particular, target vessel MI (attributed either to the stented target segment or the nonstented segment) occurred less frequently in IVUS-guided group compared with the angiographyguided group (2.2% versus 4.1%; P<0.001) of which reduction was observed both within 1 year (1.7% versus 2.9%; P<0.001) and between years 1 and 2 (0.5% versus 1.2%; P=0.002).
The incidence of clinically driven target lesion revascularization (TLR) was not different between the IVUS-guided and the angiography-guided groups within 1 year after DES implantation. However, between 1 and 2 years, clinically driven TLR was less frequent with IVUS guidance compared with angiography guidance (1.8% versus 3.2%; P=0.0002). As a result, IVUS guidance was associated with a significantly lower rate of clinically driven TLR at 2 years (5.0% versus 6.5%; P=0.01). Table 4 summarizes the results of the multivariable Cox proportional hazards regression models stratified by quintiles of the propensity score by modeling IVUS guidance. IVUS guidance was independently associated with 60%, 35%, and 28% reductions of stent thrombosis, MI, and MACE at 2 years. As shown in Figure 3 , the lower 2-year rate of MACE in the IVUS guidance group was consistent across numerous subgroups. 
DISCUSSION
In our previous report from the ADAPT-DES study, IVUS guidance was associated with a reduction in stent thrombosis, MI, and MACE within 1 year after DES implantation. In the current report, these 1-year benefits not only were maintained but increased with follow-up through 2 years. To our knowledge, 7 randomized trials and 18 registries comparing IVUS guidance and angiography guidance have been performed in the DES era. Eleven meta-analyses [7] [8] [9] [10] [11] [12] [13] of various combinations of these (the largest involving 31 283 patients) have reported reduced overall MACE with IVUS guidance, primarily through a reduction in the hard end points of death, MI, and stent thrombosis. However, limited data are available from any of the prior reports on whether the benefits of IVUS are maintained, lost or increase with extended follow-up. The only exception was from a meta-analysis of randomized trials 12 in which subgroup analysis of 3 of the 7 studies (635 total patients) found a similar benefit of IVUS guidance for MACE at 1 year (odds ratio, 0.56; 95% CI, 0.40-0.77) and 2 years (odds ratio, 0.67; 95% CI, 0.46-0.97). However, only first-generation DES were used in these 3 studies, limiting the applicability of these findings to contemporary practice. In the current large-scale study in which second-generation DES were used in two-thirds of the cases, the benefit of IVUS guidance in reducing the 2-year rate of MACE was consistent in patients treated with first-and secondgeneration DES. Moreover, stent thrombosis, MI, and clinically driven TLR and target vessel revascularization rates were either significantly reduced or tended to be reduced in the IVUS guidance group between 1 and 2 years, compared with angiography guidance alone.
In the current study using landmark analysis, there was continued divergence for all outcome. In the RESOLUTE All-Comers trial that compared the zotarolimus-eluting slow release stent to the everolimuseluting stent, the overall clinically indicated TLR was 3.7% at 1 year and 5.4% at 2 years. 14, 15 In an optical coherence tomographic study including 171 secondgeneration DES in-stent restenosis (ISR) cases, the prevalence of stent underexpansion (minimum stent area, <4 mm 2 ) was 65% at 1 year and 56% of ISR between years 1 and 2. 16 Thus, even using contemporary DES, late ISR (1-2 years) because of stent underexpansion appears to be frequent. In the PRESTIGE (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort) registry and the study by Nakamura et al, 17 the combination of stent underexpansion and ISR were important causes for stent thrombosis beyond 1 year (very late stent thrombosis). 18 In PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree), the rates of cardiac death and MI were 0.6% and 1.5% at 1 year, respectively, and 1.2% and 2.6% at 2 years, respectively, with events approximately equally attributed between stented culprit lesions and untreated nonculprit lesions. 19 Thus, the hard end points of cardiac death and MI after DES implantation continue to increase beyond 1 year. In a separate article including the same ADAPT-DES cohort as in the current study, among 263 patients who sustained a nonperiprocedural MI, 24% were because of stent thrombosis, and 22% were because of ISR (an MI caused by a very severe stenosis). 20 Also, in this study, patients with an MI had increased mortality. The significant reduction in MI with IVUS guidance in the current study (both in the first year and between years 1 and 2) was because of fewer stent thrombosis events, as well as a lower rate of target vessel-related spontaneous MIs (attributed both to the stented target segment and the nonstented segment). All together, IVUS guidance improves stent optimization that also reduces stent thrombosis and severe ISR-causing MI (target vessel MI) and subsequent death between the first and the second year after implantation.
In the prior meta-analysis by Zhang et al, 11 the benefit of IVUS guidance in reducing mortality was more pronounced in patients with complex lesions (defined as left main, bifurcation, chronic total occlusions, small vessels, or long lesions) or acute coronary syndromes. An advantage of the present large-scale all-comers study was the enrollment of large numbers of patients with complex lesion characteristics. The reduction in MACE with IVUS guidance compared with angiography guidance in our study was consistent across numerous complex lesion subsets (including left main, bifurcation, ostial, ISR, small vessels, and long lesions), although the absolute benefit of IVUS guidance tended to be greater in the complex lesion subsets with a higher absolute event rate.
The increasing benefit of IVUS with extended follow-up affects the overall cost-effectiveness of this procedure. Alberti et al 21 assessed the cost-effectiveness of IVUS guidance on DES implantation using data from the meta-analysis of Ahn et al 10 from the Italian healthcare payer perspective. IVUS was more cost-effective in patients with higher risk comorbid conditions, including those with diabetes mellitus, renal insufficiency, and acute coronary syndromes. If the IVUS benefit was assumed to be limited to the first year, the incremental cost-effectiveness ratio per quality-adjusted life year gained was €9624, lower than the €25 000 per quality-adjusted life year used in Italy as its willingness-to-pay threshold. Outcomes were sensitive to the probability of having an MI or repeat revascularization after 1 year; and IVUS became a dominant treatment option, providing improved outcomes at lower costs if the benefits of IVUS continued beyond 1 year as seen in the current analysis.
Study Limitations
The present study was not a randomized study, and the decision to use and manner of IVUS use was according to the operator's discretion. Although the major results were consistent after propensity adjustment, we cannot exclude bias from unmeasured confounders. There was no prespecified IVUS criteria for the optimal stenting. Although death, MI, and stent thrombosis events were centrally adjudicated events, revascularization was not, adding some imprecision to this end point. Finally, IVUS use was unblinded, and some degree of event ascertainment bias cannot be excluded.
Conclusions
In the large-scale, all-comers ADAPT-DES study, IVUS guidance of DES implantation was associated with a reduction in stent thrombosis, MI, and MACE at 1 year that increased with longer term follow-up to 2 years compared with angiography guidance alone. Along with meta-analyses of randomized trials demonstrating improved shortterm outcomes, these extended follow-up data emphasize the improved clinical outcomes that may be achieved with IVUS guidance in the contemporary DES era. 
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